Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06699680 | Phase 1 Study of PRX019 in Healthy Adult Volunteers | PHASE1 | COMPLETED | 50 | — | — | Nov 8, 2024 | Jan 16, 2026 | May 14, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| PRX019, single dose | EXPERIMENTAL | Specified dose on specified days |
| PRX019, multiple dose | EXPERIMENTAL | Specified dose on specified days |
| Name | Type | Description |
|---|---|---|
| PRX019 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examination, and clinical laboratory tests obtained during the screening period * Participant is willing and able to adhere to the study visit schedule a...